{"id":"W3092889157","doi":"10.1136/annrheumdis-2020-eular.1432","title":"SAT0139 AGE-BASED (<65 VS ≥65 YEARS) INCIDENCE OF INFECTIONS AND SERIOUS INFECTIONS IN TOFACITINIB-, ADALIMUMAB- AND PLACEBO-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF PHASE 2, PHASE 3 AND PHASE 3B/4 TOFACITINIB STUDIES","year":2020,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Medicine; Tofacitinib; Adalimumab; Etanercept; Internal medicine; Janus kinase inhibitor; Rheumatoid arthritis; Placebo; Post-hoc analysis; Adverse effect; Infliximab; Incidence (geometry); Surgery; Tumor necrosis factor alpha","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004112791,0.0008569175,0.00254453,0.0006754764,0.0003026674,0.001271454,0.0005977087,0.000813071,0.004673786],"category_scores_gemma":[0.003304118,0.0004768349,0.006878746,0.0007360353,0.0003550574,0.001103056,0.0006374862,0.001528654,0.0002920553],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003751882,"about_ca_system_score_gemma":0.0006006196,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001090442,"about_ca_topic_score_gemma":0.002294802,"domain_scores_codex":[0.9970726,0.001636501,0.0002554785,0.0005243912,0.0002312566,0.0002797636],"domain_scores_gemma":[0.9963382,0.002238136,0.0006510207,0.0002645317,0.0001961538,0.0003119124],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7816656,0.0007879558,0.1665788,0.0009094927,0.02934601,0.0002379549,0.0001404804,0.001009822,0.004093621,0.0001707386,0.001227522,0.01383194],"study_design_scores_gemma":[0.0609648,0.09563991,0.7965103,0.0002036879,0.03623506,0.0005527917,0.0005667074,0.003576306,0.002005379,0.0005473236,0.003065782,0.0001319204],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941298,0.002861479,0.0002765525,0.0000745154,0.0001330617,0.00008402236,0.001513613,0.00001683997,0.000910209],"genre_scores_gemma":[0.997269,0.0004424972,0.0001730259,0.0001044782,0.00008349667,0.00007832596,0.001055301,0.000010393,0.0007835117],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004673786,"threshold_uncertainty_score":0.02175081,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02664503564720795,"score_gpt":0.3276468873072486,"score_spread":0.3010018516600406,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}